1-5 Apr 2017 - Takis to present New Data on Epitope-based Cancer Vaccines at AACR Annual Meeting, Washington DC

In collaboration with Biogem, Dr Luigi Aurisicchio, CEO/CSO at Takis, will present the Poster: "Epitope-minigenes for optimal induction of the immune response against tumor associated antigens and neoantigens", abstract #5639 at the 110th American Association for Cancer Research (AACR) Annual Meeting.

Meeting Washington DC Takisbiotech

"Our results show that it is possible to select immunogenic Epitopes contained within Tumor Associated antigens and achieve significant antitumor effects." - declared Luigi Aurisicchio. "This can be achieved through an algorythm that allows the selection of unique, unshared epitopes in human proteome, thus avoiding side-effects and autoimmunity. Importantly, we have also developed a pipeline able to identify epitopes contained in mutated antigens (neoantigens) and have shown the potency of a personalized cancer vaccines in mouse models, including our Immunoavatar".

These data may open new avenues for Cancer Patients in combination with Immune Checkpoint inhibitors.

Come to our poster, meet Takis and evaluate a number of opportunities! Here the coordinates:

Session Title:       Adaptive Immunity to Cancer

Session Start Time: 4/3/2017 08:00:00 AM
Session End Time: 4/3/2017 12:00:00 PM
Location: Poster Section 29
Poster Board Number: 9
Poster Number: 1690

 

 For more information point your browser to: www.aacr.org

Takis Biotech

Takis Services